Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success

DOI: https://doi.org/10.1007/s11912-024-01544-3

2024-06-09

Current Oncology Reports

Abstract:This report highlights several of the recent therapeutic advancements in the treatment of BRAF -mutant tumors, discusses the most common adverse events observed with BRAF -targeted agents, and suggests strategies to manage and mitigate treatment-related toxicities.

oncology

What problem does this paper attempt to address?

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Gongda Xue,Reto Kohler,Fengyuan Tang,Debby Hynx,Yuhua Wang,Francesca Orso,Vincent Pretre,Reto Ritschard,Petra Hirschmann,Peter Cron,Tim Roloff,Reinhard Dummer,Mario Mandala,Sandrine Bichet,Christel Genoud,Alexandra G. Meyer,Manuele G. Muraro,Giulio C. Spagnoli,Daniela Taverna,Curzio Ruegg,Taha Merghoub,Daniela Massi,Huifang Tang,Mitchell P. Levesque,Stephan Dirnhofer,Alfred Zippelius,Brian A. Hemmings,Andreas Wicki

DOI: https://doi.org/10.18632/oncotarget.18213

2017-01-01

Oncotarget

Abstract:BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi) were recently approved for therapy of metastatic melanomas harbouring the oncogenic BRAFV600 mutation. Although these therapies have shown pronounced therapeutic efficacy, the limited durability of the response indicates an acquired drug resistance that still remains mechanistically poorly understood at the molecular level. We conducted transcriptome gene profiling in BRAFi-treated melanoma cells and identified that Mer tyrosine kinase (MerTK) is specifically upregulated. MerTK overexpression was demonstrated not only in melanomas resistant to BRAFi monotherapy (5 out of 10 samples from melanoma patients) but also in melanoma resistant to BRAFi+MEKi (1 out of 3), although MEKi alone does not affect MerTK. Mechanistically, BRAFi-induced activation of Zeb2 stimulates MerTK in BRAFV600 melanoma through mTORC1-triggered activation of autophagy. Co-targeting MerTK and BRAFV600 significantly reduced tumour burden in xenografted mice, which was pheno-copied by co-inhibition of autophagy and mutant BRAFV600.
Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors

Claire Glen,Yun Yi Tan,Ashita Waterston,Thomas R. Jeffry Evans,Robert J. Jones,Mark C. Petrie,Ninian N. Lang

DOI: https://doi.org/10.1016/j.jaccao.2022.01.096

2022-03-01

Abstract:Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized melanoma treatment. Approximately half of patients with melanoma harbor a BRAF gene mutation with subsequent dysregulation of the RAF-MEK-ERK signaling pathway. Targeting this pathway with BRAF and MEK blockade results in control of cell proliferation and, in most cases, disease control. These pathways also have cardioprotective effects and are necessary for normal vascular and cardiac physiology. BRAF and MEK inhibitors are associated with adverse cardiovascular effects including hypertension, left ventricular dysfunction, venous thromboembolism, atrial arrhythmia, and electrocardiographic QT interval prolongation. These effects may be underestimated in clinical trials. Baseline cardiovascular assessment and follow-up, including serial imaging and blood pressure assessment, are essential to balance optimal anti-cancer therapy while minimizing cardiovascular side effects. In this review, an overview of BRAF/MEK inhibitor-induced cardiovascular toxicity, the mechanisms underlying these, and strategies for surveillance, prevention, and treatment of these effects are provided.

oncology,cardiac & cardiovascular systems
Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity

Isabelle Senechal,Maria Sol Andres,Jieli Tong,Sivatharshini Ramalingam,Muhummad Sohaib Nazir,Stuart D. Rosen,Kate Young,Praveena Idaikkadar,James Larkin,Alexander R. Lyon

DOI: https://doi.org/10.1007/s11912-024-01599-2

2024-09-25

Current Oncology Reports

Abstract:In this review article we describe the cardiovascular adverse events associated with BRAF and MEK inhibitors as well as their pathophysiologic mechanisms and provide up to date guidance for risk stratified surveillance of patients on treatment and the optimal management of emergent cardiotoxicities.

oncology
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem

Viswanath Reddy Belum,Alyssa Fischer,Jennifer Nam Choi,Mario E. Lacouture

DOI: https://doi.org/10.1007/s11912-013-0308-6

2013-03-06

Current Oncology Reports

Abstract:The development of targeted therapies has ushered in a new era in the management of melanoma. Inhibitors of the RAS-RAF-MEK-ERK pathway have taken the center stage with development at a rapid pace. Vemurafenib was recently approved by regulatory agencies, and other agents (e.g. dabrafenib) are in various stages of clinical testing. These agents are producing remarkable results for patients, but are also presenting new challenges. Clinical toxicities and drug resistance are topmost issues. Some of the most common and vivid representations of adverse events to these agents are the dermatologic manifestations. Published trials and initial observations reflect a toxicity profile (e.g. squamous cell carcinomas/keratoacanthomas, maculopapular rashes, hyperkeratosis) that is distinct from cutaneous toxicities from EGFR and mTOR inhibitors (acneiform rash, paronychia, xerosis). Their management extends beyond conservative treatment and includes specific physical and surgical treatment modalities, skill sets unique to dermatologists. All these pose significant challenges to clinicians, and sound knowledge of such toxicities and their management will likely result in improved patient outcomes and quality of life. In this manuscript, we provide an overview of the emerging scientific literature on dermatological adverse events arising out of BRAF inhibition.

oncology
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Khine S. Shan,Tauseef U. Rehman,Stan Ivanov,Gelenis Domingo,Luis E. Raez

DOI: https://doi.org/10.3390/ijms25010624

IF: 5.6

2024-01-04

International Journal of Molecular Sciences

Abstract:The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation, growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause downstream activation of kinases, leading to uncontrolled cellular growth and carcinogenesis. Therefore, inhibition of BRAF and the downstream substrate MEK has been shown to be effective in controlling tumor growth and proliferation. Over the last decade, several BRAF and MEK inhibitors have been investigated, ranging from primarily melanoma to various cancer types with BRAF alterations. This subsequently led to several Food and Drug Administration (FDA) approvals for BRAF/MEK inhibitors for melanoma, non-small cell lung cancer, anaplastic thyroid cancer, colorectal cancer, histiocytosis neoplasms, and finally, tumor-agnostic indications. Here, this comprehensive review will cover the developments of BRAF and MEK inhibitors from melanomas to tumor-agnostic indications, novel drugs, challenges, future directions, and the importance of those drugs in personalized medicine.

biochemistry & molecular biology,chemistry, multidisciplinary
Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Jingjing Qu,Qian Shen,Yuping Li,Farhin Shaheed Kalyani,Li Liu,Jianya Zhou,Jianying Zhou

DOI: https://doi.org/10.3389/fonc.2022.911303

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:BackgroundLimited treatment outcome data is available for advanced non-small cell lung cancer (NSCLC) patients with BRAF V600E mutations. In this multicenter study, we describe therapeutic options and survival outcomes for patients with mutated BRAF V600E. MethodThis was a retrospective study in which BRAF V600E-mutated advanced NSCLC patients were retrospectively recruited between January 2015 and December 2021 and had their clinical characteristics, co-mutations, and treatment efficacy assessed. ResultsFifty-three patients with BRAF V600E-mutant advanced NSCLC were included in the study, of which 64.2% were non-smokers, and the BRAF V600E mutation was more prevalent in men (52.8%). In addition, 96.2% of the patients had adenocarcinoma, and most (96.2%) received first-line therapy (23.5% anti-BRAF), with a progression-free survival (PFS) and overall survival (OS) of 10.0 [95% confidence interval (CI): 1.5-36.0 months] and 24.0 months [95% CI: 3.0-53.0 months], respectively. Twenty-three patients (43.4%) received second-line treatment (39.1% anti-BRAF), and PFS and OS were 5.0 [95% CI: 1.0-21.0 months] and 13.0 months [95% CI: 1.5-26.0 months], respectively. BRAF and MEK-targeted therapy (dabrafenib plus trametinib) produced longer PFS compared with that of chemotherapy with or without bevacizumab as a first-line (NA vs. 4.0 months, P = 0.025) or second-line therapy (6.0 vs. 4.6 months, P = 0.017). NSCLC patients harboring driver oncogene mutations such as BRAF V600E, EGFR, or ALK should be treated using targeted therapies. Concurrent TP53 mutations were the most common, affecting 11.3% (n = 6) of the patients, followed by EGFR 19 Del (n = 5). Patients with concurrent mutations had shorter PFS (9.0 vs. 10.0 months, P = 0.875) and OS (14.0 vs. 15.0 months, P = 0.555) than those without these mutations. ConclusionThese results suggest that combined BRAF- and MEK-targeted therapy is effective in BRAF V600E-mutated advanced NSCLC patients. Dabrafenib and trametinib re-challenge is also an option for patients with BRAF V600E-mutated NSCLC.
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Sunilkumar Kakadia,Naveen Yarlagadda,Ramez Awad,Madappa Kundranda,Jiaxin Niu,Boris Naraev,Lida Mina,Tomislav Dragovich,Mark Gimbel,Fade Mahmoud

DOI: https://doi.org/10.2147/ott.s182721

IF: 4

2018-10-01

OncoTargets and Therapy

Abstract:Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to treat patients with BRAF V600-mutated advanced melanoma. Both genetic and epigenetic alterations play a major role in resistance to BRAF inhibitors by reactivation of the MAPK and/or the PI3K-Akt pathways. The role of BRAF inhibitors in modulating the immunomicroenvironment and perhaps enhancing the efficacy of checkpoint inhibitors is gaining interest. This article provides a comprehensive review of mechanisms of resistance to BRAF and MEK inhibitors in melanoma and summarizes landmark trials that led to the FDA approval of BRAF and MEK inhibitors in metastatic melanoma.

oncology,biotechnology & applied microbiology
Current Advances in the Treatment of BRAF-Mutant Melanoma

Hima Patel,Nour Yacoub,Rosalin Mishra,Aaron White,Long Yuan,Samar Alanazi,Joan T. Garrett

DOI: https://doi.org/10.3390/cancers12020482

2020-02-19

Cancers

Abstract:Melanoma is the most lethal form of skin cancer. Melanoma is usually curable with surgery if detected early, however, treatment options for patients with metastatic melanoma are limited and the five-year survival rate for metastatic melanoma had been 15–20% before the advent of immunotherapy. Treatment with immune checkpoint inhibitors has increased long-term survival outcomes in patients with advanced melanoma to as high as 50% although individual response can vary greatly. A mutation within the MAPK pathway leads to uncontrollable growth and ultimately develops into cancer. The most common driver mutation that leads to this characteristic overactivation in the MAPK pathway is the B-RAF mutation. Current combinations of BRAF and MEK inhibitors that have demonstrated improved patient outcomes include dabrafenib with trametinib, vemurafenib with cobimetinib or encorafenib with binimetinib. Treatment with BRAF and MEK inhibitors has met challenges as patient responses began to drop due to the development of resistance to these inhibitors which paved the way for development of immunotherapies and other small molecule inhibitor approaches to address this. Resistance to these inhibitors continues to push the need to expand our understanding of novel mechanisms of resistance associated with treatment therapies. This review focuses on the current landscape of how resistance occurs with the chronic use of BRAF and MEK inhibitors in BRAF-mutant melanoma and progress made in the fields of immunotherapies and other small molecules when used alone or in combination with BRAF and MEK inhibitors to delay or circumvent the onset of resistance for patients with stage III/IV BRAF mutant melanoma.

oncology
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Matthew Dankner,April A. N. Rose,Shivshankari Rajkumar,Peter M. Siegel,Ian R. Watson

DOI: https://doi.org/10.1038/s41388-018-0171-x

IF: 8.756

2018-03-15

Oncogene

Abstract:The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation. Non-V600 BRAF mutants are found in many cancers, and are more prevalent than V600 mutations in certain tumor types. For example, between 50–80% of BRAF mutations in non-small cell lung cancer and 22–30% in colorectal cancer encode for non-V600 mutants. As next generation sequencing becomes increasingly used in clinical practice, oncologists are frequently identifying non-V600 BRAF mutations in their patient’s tumors, but are uncertain of viable therapeutic options that could be employed for optimal treatment. From recent studies, a new classification system is emerging for BRAF mutations based on biochemical and signaling mechanisms associated with these mutants. Class I BRAF mutations affect amino acid V600 and signal as RAS-independent active monomers, class II mutations function as RAS-independent activated dimers, and class III mutations are kinase impaired but increase signaling through the MAPK pathway due to enhanced RAS binding and subsequent CRAF activation. These distinct classes of BRAF mutations predict response to targeted therapies and have important implications for future drug development. Herein, we discuss pre-clinical and clinical findings that may lead to improved treatments for all classes of BRAF mutant cancers.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review

Yanyan Gao,Hua Zheng

DOI: https://doi.org/10.1016/j.critrevonc.2024.104484

Abstract:The classical mitogen-activated protein kinase (MAPK) signaling pathway, the Ras/Raf/MEK (mitogen-activated protein kinase/ERK kinase)/ERK protein kinase cascade, is a conserved cascade that regulates cell growth, differentiation, and proliferation. The significance of BRAF in cancer was established with the discovery of cancer-activating mutations in BRAF in several human tumors in 2002. Currently, BRAF is recognized as a driver mutation that affects cancer phenotypes in different ways, making it an important therapeutic target for cancer. BRAF-selective inhibitors have shown promise in clinical trials involving patients with metastatic melanoma. However, resistance mechanisms to BRAF inhibitors therapy have resulted in short-lived therapeutic responses. Further in-depth research is imperative to explore resistance mechanisms that oppose the effectiveness of BRAF inhibitors. Metabolic reprogramming has emerging role in BRAF-mutant cancers. In particular, mitochondrial metabolism and its closely related signaling pathways mediated by mitochondria have become recognized as potential new targets for treating BRAF-mutant cancers. This review, examines the progress in understanding BRAF mutations in cancer, the clinicopathological correlation of BRAF inhibitors, and recent advances in mitochondrial metabolism, mitochondrial dynamics and mitochondrial mediated death in BRAF-mutant cancer. This review will inform future cancer research and lay the foundation for novel treatment combinations of BRAF-mutant cancers.
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma

Alexander W Loftus,Mehrdad Zarei,Hanna Kakish,Omid Hajihassani,Jonathan J Hue,Christina Boutros,Hallie J Graor,Faith Nakazzi,Tsegaw Bahlibi,Jordan M Winter,Luke D Rothermel

DOI: https://doi.org/10.1016/j.ctrv.2024.102795

Abstract:Melanoma metabolism can be reprogrammed by activating BRAF mutations. These mutations are present in up to 50% of cutaneous melanomas, with the most common being V600E. BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation. Prior to the development of targeted anti-BRAF therapies, these mutations were associated with accelerated clinical disease in the metastatic setting. Combination BRAF and MEK inhibition is a first line treatment option for locally advanced or metastatic melanoma harboring targetable BRAF mutations. This therapy shows excellent response rates but these responses are not durable, with almost all patients developing resistance. When BRAF mutated melanoma cells are inhibited with targeted therapies the metabolism of those cells also changes. These cells rely less on glycolysis for energy production, and instead shift to a mitochondrial phenotype with upregulated TCA cycle activity and oxidative phosphorylation. An increased dependence on glutamine utilization is exhibited to support TCA cycle substrates in this metabolic rewiring of BRAF mutated melanoma. Herein we describe the relevant core metabolic pathways modulated by BRAF inhibition. These adaptive pathways represent vulnerabilities that could be targeted to overcome resistance to BRAF inhibitors. This review evaluates current and future therapeutic strategies that target metabolic reprogramming in melanoma cells, particularly in response to BRAF inhibition.
The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells

Abygail G Chapdelaine,Geng Chia Ku,Gongqin Sun,Marina K Ayrapetov

DOI: https://doi.org/10.3390/cancers15245805

2023-12-12

Abstract:The BRAF V600E mutation is frequently found in cancer. It activates the MAPK pathway and promotes cancer cell proliferation, making BRAF an excellent target for anti-cancer therapy. While BRAF-targeted therapy is highly effective for melanoma, it is often ineffective against other cancers harboring the BRAF mutation. In this study, we evaluate the effectiveness of a proteolysis targeting chimera (PROTAC), SJF-0628, in directing the degradation of mutated BRAF across a diverse panel of cancer cells and determine how these cells respond to the degradation. SJF-0628 treatment results in the degradation of BRAF V600E and a decrease in Mek activation in all cell lines tested, but the effects of the treatment on cell signaling and cell proliferation are cell-line-specific. First, BRAF degradation killed DU-4475 and Colo-205 cells via apoptosis but only partially inhibited the proliferation of other cancer cell lines. Second, SJF-0628 treatment resulted in co-degradation of MEK in Colo-205 cells but did not have the same effect in other cell lines. Finally, cell lines partially inhibited by BRAF degradation also contain other oncogenic drivers, making them multi-driver cancer cells. These results demonstrate the utility of a PROTAC to direct BRAF degradation and reveal that multi-driver oncogenesis renders some colorectal cancer cells resistant to BRAF-targeted treatment.
BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Aphrothiti J. Hanrahan,Ziyu Chen,Neal Rosen,David B. Solit

DOI: https://doi.org/10.1038/s41571-023-00852-0

IF: 78.8

2024-01-27

Nature Reviews Clinical Oncology

Abstract:In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the treatment of adult and paediatric patients (≥6 years of age) with unresectable or metastatic BRAF V600E -mutant solid tumours, except for BRAF V600E -mutant colorectal cancers. The histology-agnostic approval of dabrafenib plus trametinib marks the culmination of two decades of research into the landscape of BRAF mutations in human cancers, the biochemical mechanisms underlying BRAF-mediated tumorigenesis, and the clinical development of selective RAF and MEK inhibitors. Although the majority of patients with BRAF V600E -mutant tumours derive clinical benefit from BRAF inhibitor-based combinations, resistance to treatment develops in most. In this Review, we describe the biochemical basis for oncogenic BRAF-induced activation of MAPK signalling and pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and acquired resistance to BRAF inhibitors. We also discuss novel RAF inhibitors and drug combinations designed to delay the emergence of treatment resistance and/or expand the population of patients with BRAF -mutant cancers who benefit from molecularly targeted therapies.

oncology
Alpha-1 antitrypsin Null mutations and severity of emphysema.

L. Fregonese,J. Stolk,R. Frants,B. Veldhuisen

DOI: https://doi.org/10.1016/j.rmed.2008.01.009

IF: 4.3

2008-06-01

Respiratory Medicine

Abstract:
Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function

Sophie Bromberger,Yuliia Zadorozhna,Julia Maria Ressler,Silvio Holzner,Arkadiusz Nawrocki,Nina Zila,Alexander Springer,Martin Røssel Larsen,Klaudia Schossleitner

DOI: https://doi.org/10.26508/lsa.202402671

IF: 5.781

2024-06-07

Life Science Alliance

Abstract:Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. The blood vessel lining is in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with dabrafenib or encorafenib. Together, these findings provide insights into the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.

biology
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

I Manousaridis,S Mavridou,S Goerdt,M Leverkus,J Utikal

DOI: https://doi.org/10.1111/j.1468-3083.2012.04546.x

Abstract:Mutations in genes encoding for proteins along the RAS-RAF-MEK-ERK pathway have been detected in a variety of tumor entities, including malignant melanoma, thyroid, colonic and ovarian carcinomas, and some sarcomas. Thus, a number of inhibitors of this pathway have been developed, whose antitumor potential is currently being assessed in different clinical trials. Up to now one drug of this category (vemurafenib) has been approved by the FDA and the European Commission for late-stage melanoma. Although these new targeted anticancer therapies are generally considered to be safe and well tolerated, certain toxicities have been attributed to them, with cutaneous side effects being perhaps the most frequent amongst them. Based on results of clinical trials and on case series, a distinct profile of cutaneous toxicity has been observed, which is similar to that of EGFR and multikinase inhibitors. As exanthema, palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, xerosis, pruritus, photosensitivity, and paronychia, can be controlled in most cases with common conservative modalities, special attention should be given to the early detection of epithelial skin tumors (mainly keratoakanthomas) that can be induced during therapy with these agents. This report reviews all current published data on cutaneous side effects of RAS-RAF-MEK-ERK pathway inhibitors, and attempts to provide the clinician with clear hints for their management.
Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States

Sanjay Chandrasekaran,You-Li Ling,Jackson Tang

DOI: https://doi.org/10.1097/cmr.0000000000000990

2024-08-31

Melanoma Research

Abstract:Despite recent mortality declines, the incidence of cutaneous melanoma continues to rise as it remains the most common and fatal skin cancer [ 1 ]. BRAF mutations are detected in up to approximately 40–50% of patients with cutaneous melanoma [ 2–5 ]. The most common BRAF mutations occur on exon 15 as single nucleotide substitutions at codon 600 (valine) to glutamic acid ( BRAF V600E, most common), lysine ( BRAF V600K), or arginine ( BRAF V600R, least common) [ 4–6 ]. The role of BRAF mutations in melanogenesis has been widely described and largely attributed to the resulting deregulated activation of downstream MEK/ERK effectors within the mitogen-activated protein kinase (MAPK) pathway, thereby driving cell proliferation, survival, and malignant growth [ 7 ].

dermatology,oncology,medicine, research & experimental
The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

Saber Imani,Ghazaal Roozitalab,Mahdieh Emadi,Atefeh Moradi,Payam Behzadi,Parham Jabbarzadeh Kaboli

DOI: https://doi.org/10.3389/fonc.2024.1504142

IF: 4.7

2024-11-09

Frontiers in Oncology

Abstract:Melanoma, a highly aggressive form of skin cancer, poses a significant global health burden, with 331,647 new cases and 58,645 deaths reported in 2022. The development of melanoma is influenced by various factors, including sunlight exposure and BRAF V600 mutations that activate the MAPK/ERK pathway. The introduction of BRAF and MEK inhibitors has revolutionized the treatment landscape for melanoma patients. However, innate and acquired therapeutic resistance remains a significant challenge. This review provides a comprehensive overview of the current state of BRAF-targeted therapies in melanoma, highlighting the efficacy and limitations of FDA-approved combinations of BRAF and MEK inhibitors such as vemurafenib, dabrafenib, trametinib, and cobimetinib. The review also explores the off-target effects of BRAF inhibitors on endothelial cells, emphasizing the need for more selective therapies to minimize vascular complications and metastatic potential. The article also discusses potential druggable targets, including ERK5, CD73, ALDH1A1, PLA1A, and DMKN, which are promising in addressing diagnostic hurdles and guiding personalized therapeutic decisions. Recent studies on regorafenib, ERK5 signaling, and CD73 inhibition are highlighted as novel strategies to overcome resistance and improve treatment outcomes. The review also delves into the role of advanced therapeutic tools, such as mRNA vaccines and CRISPR-Cas9, in revolutionizing personalized oncology by targeting specific genetic mutations and enhancing immune responses against melanoma. The ongoing synergy between advancing research, targeted interventions, strategic treatment combinations, and cost-effectiveness evaluations offers a promising pathway to elevate patient outcomes in the persistent battle against melanoma significantly.

oncology
Deep brain stimulation for movement disorders.

P. Starr,J. Vitek,R. Bakay

DOI: https://doi.org/10.1016/S1042-3680(18)30273-0

IF: 3.348

1998-04-01

Neurosurgery Clinics of North America

Abstract:
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

Meredith S. Pelster,Rodabe N. Amaria

DOI: https://doi.org/10.1177/1758835919830826

2019-01-01

Therapeutic Advances in Medical Oncology

Abstract:The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint inhibitors have changed the management of advanced stage melanoma and improved the outcomes of patients with this malignancy. However, both therapeutic approaches have limitations, including a limited duration of benefit in subsets of BRAF-mutant melanoma patients treated with targeted therapy and a lower overall response rate without a clear predictive biomarker in patients treated with checkpoint inhibitors. Preclinical and translational data have shown that BRAFis and MEKis alter the tumor microenvironment to make it more amenable to immunotherapy and have provided the scientific rationale for combing BRAFis and MEKis with immunotherapy. In this review, the initial studies demonstrating the impact of BRAFis and MEKis on the expression of melanoma differentiation antigens, T-cell infiltration, and the balance of immune stimulatory and immune suppressive cells and cytokines are addressed. Preclinical work on the combination of targeted therapy with BRAFis and MEKis with immunotherapy are reviewed, highlighting improved tumor responses in mouse models of BRAF-mutated melanoma treated with combinatorial strategies. Lastly, data from early clinical trials of combined targeted therapy and immunotherapy are discussed, focusing on response rates and toxicities.

oncology

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors

Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated Cardiotoxicity

Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Current Advances in the Treatment of BRAF-Mutant Melanoma

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review

Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma

The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Alpha-1 antitrypsin Null mutations and severity of emphysema.

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies

Deep brain stimulation for movement disorders.

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials